$1.09
1.83%
Downside
Day's Volatility :4.46%
Upside
2.68%
32.66%
Downside
52 Weeks Volatility :69.42%
Upside
54.58%
Period | Femasys Inc | Index (Russel 2000) |
---|---|---|
3 Months | -2.63% | 0.0% |
6 Months | -29.75% | 0.0% |
1 Year | -35.47% | 0.0% |
3 Years | -84.14% | -21.4% |
Market Capitalization | 24.7M |
Book Value | $0.51 |
Earnings Per Share (EPS) | -0.84 |
Wall Street Target Price | 8.75 |
Profit Margin | 0.0% |
Operating Margin TTM | -2023.69% |
Return On Assets TTM | -59.54% |
Return On Equity TTM | -138.37% |
Revenue TTM | 950.1K |
Revenue Per Share TTM | 0.05 |
Quarterly Revenue Growth YOY | -30.9% |
Gross Profit TTM | 764.3K |
EBITDA | -16.1M |
Diluted Eps TTM | -0.84 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.75 |
EPS Estimate Next Year | -0.46 |
EPS Estimate Current Quarter | -0.17 |
EPS Estimate Next Quarter | -0.18 |
What analysts predicted
Upside of 702.75%
FY19 | Y/Y Change | |
---|---|---|
Revenue | 929.1K | - |
Net Income | -11.3M | - |
Net Profit Margin | -1.2K% | - |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 1.0M | ↑ 11.72% |
Net Income | -6.9M | ↓ 38.65% |
Net Profit Margin | -666.24% | ↑ 547.02% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 1.2M | ↑ 13.66% |
Net Income | -7.5M | ↑ 9.01% |
Net Profit Margin | -638.97% | ↑ 27.27% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 1.2M | ↑ 2.25% |
Net Income | -11.4M | ↑ 51.16% |
Net Profit Margin | -944.62% | ↓ 305.65% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 1.1M | ↓ 11.13% |
Net Income | -14.2M | ↑ 25.04% |
Net Profit Margin | -1.3K% | ↓ 384.44% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 294.0K | ↑ 25.5% |
Net Income | -2.9M | ↓ 1.44% |
Net Profit Margin | -970.29% | ↑ 265.26% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 320.5K | ↑ 9.02% |
Net Income | -2.9M | ↑ 1.44% |
Net Profit Margin | -902.77% | ↑ 67.52% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 244.4K | ↓ 23.76% |
Net Income | -4.0M | ↑ 38.13% |
Net Profit Margin | -1.6K% | ↓ 732.89% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 213.1K | ↓ 12.79% |
Net Income | -4.4M | ↑ 10.35% |
Net Profit Margin | -2.1K% | ↓ 433.9% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 271.1K | ↑ 27.23% |
Net Income | -3.6M | ↓ 18.39% |
Net Profit Margin | -1.3K% | ↑ 742.01% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 221.5K | ↓ 18.31% |
Net Income | -4.7M | ↑ 30.14% |
Net Profit Margin | -2.1K% | ↓ 787.53% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 12.6M | - |
Total Liabilities | 58.0M | - |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 7.6M | ↓ 39.85% |
Total Liabilities | 59.4M | ↑ 2.42% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 28.6M | ↑ 275.7% |
Total Liabilities | 2.2M | ↓ 96.22% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 16.9M | ↓ 40.88% |
Total Liabilities | 1.7M | ↓ 26.34% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 27.8M | ↑ 64.28% |
Total Liabilities | 9.4M | ↑ 468.84% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 13.9M | ↓ 17.92% |
Total Liabilities | 1.5M | ↓ 8.57% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 14.3M | ↑ 3.22% |
Total Liabilities | 1.4M | ↓ 4.87% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 14.9M | ↑ 3.77% |
Total Liabilities | 4.4M | ↑ 206.72% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 27.8M | ↑ 86.86% |
Total Liabilities | 9.4M | ↑ 113.23% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 24.4M | ↓ 12.2% |
Total Liabilities | 8.8M | ↓ 6.8% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 20.3M | ↓ 16.8% |
Total Liabilities | 9.0M | ↑ 3.0% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -11.0M | - |
Investing Cash Flow | 12.3M | - |
Financing Cash Flow | -127.8K | - |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -4.9M | ↓ 55.18% |
Investing Cash Flow | 968.3K | ↓ 92.14% |
Financing Cash Flow | 871.6K | ↓ 782.14% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -7.9M | ↑ 60.77% |
Investing Cash Flow | -306.9K | ↓ 131.69% |
Financing Cash Flow | 29.7M | ↑ 3307.16% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -10.7M | ↑ 35.32% |
Investing Cash Flow | -407.5K | ↑ 32.79% |
Financing Cash Flow | -681.6K | ↓ 102.3% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -2.6M | ↓ 7.68% |
Investing Cash Flow | -62.9K | ↓ 32.95% |
Financing Cash Flow | -144.1K | ↑ 75.79% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -2.7M | ↑ 3.53% |
Investing Cash Flow | -62.9K | ↑ 0.0% |
Financing Cash Flow | 3.3M | ↓ 2423.9% |
Sell
Neutral
Buy
Femasys Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Femasys Inc | 1.83% | -29.75% | -35.47% | -84.14% | -90.75% |
Intuitive Surgical, Inc. | 0.53% | 24.56% | 63.66% | 42.45% | 174.56% |
Resmed Inc. | -6.24% | 24.62% | 59.67% | -8.24% | 77.02% |
Becton, Dickinson And Company | 0.42% | -1.45% | -10.38% | -1.46% | -4.55% |
West Pharmaceutical Services Inc | -1.83% | -24.47% | -22.57% | -29.02% | 110.73% |
Alcon Ag | 0.81% | 16.03% | 28.7% | 24.02% | 70.71% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Femasys Inc | NA | NA | NA | -0.75 | -1.38 | -0.6 | NA | 0.51 |
Intuitive Surgical, Inc. | 82.69 | 82.69 | 4.14 | 6.65 | 0.16 | 0.08 | NA | 41.4 |
Resmed Inc. | 33.76 | 33.76 | 1.96 | 7.71 | 0.23 | 0.13 | 0.01 | 33.11 |
Becton, Dickinson And Company | 47.84 | 47.84 | 1.1 | 13.11 | 0.06 | 0.03 | 0.02 | 89.5 |
West Pharmaceutical Services Inc | 42.18 | 42.18 | 5.14 | 6.51 | 0.2 | 0.11 | 0.0 | 35.49 |
Alcon Ag | 43.82 | 43.82 | 3.62 | 3.05 | 0.05 | 0.03 | 0.0 | 42.35 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Femasys Inc | Buy | $24.7M | -90.75% | NA | 0.0% |
Intuitive Surgical, Inc. | Buy | $173.0B | 174.56% | 82.69 | 27.65% |
Resmed Inc. | Buy | $34.3B | 77.02% | 33.76 | 21.79% |
Becton, Dickinson And Company | Buy | $68.9B | -4.55% | 47.84 | 7.13% |
West Pharmaceutical Services Inc | Buy | $21.5B | 110.73% | 42.18 | 18.25% |
Alcon Ag | Buy | $48.1B | 70.71% | 43.82 | 11.44% |
Insights on Femasys Inc
Revenue is down for the last 2 quarters, 271.14K → 221.48K (in $), with an average decrease of 18.3% per quarter
Netprofit is down for the last 2 quarters, -3.59M → -4.68M (in $), with an average decrease of 30.1% per quarter
In the last 1 year, Intuitive Surgical, Inc. has given 63.0% return, outperforming this stock by 107.5%
In the last 3 years, Intuitive Surgical, Inc. has given 42.4% return, outperforming this stock by 126.5%
CM Management, LLC
Clear Creek Investment Mgmt LLC
Vanguard Group Inc
Geode Capital Management, LLC
Northern Trust Corp
State Street Corp
our experienced management team has over 200 years of collective industry experience with extensive focus in medical devices. the pioneering and collaborative efforts of the management team have created an organization that strives for integrity in all actions, innovation in development activities, excellence in operations, and the highest quality products. the team is complemented by world-class medical advisors. our products have been organically conceived, researched and developed by the company and all manufacturing activities are conducted to ensure compliance with the u.s. food and drug administration (fda) per the requirements of 21 cfr 820, as well as iso 13485. femasys has achieved significant milestones to date, including numerous issued patents and filings, recruitment of a team of experts, clearance of multiple regulatory filings by the u.s. food and drug administration (fda), european union, canada, and japan with other select countries in process. making a difference in t
Organization | Femasys Inc |
Employees | 32 |
CEO | Ms. Kathy Lee-Sepsick M.B.A. |
Industry | Miscellaneous |
Generations Bancorp Ny Inc
$1.09
-1.8%
Innovator Us Equity Accelerated Etf - April
$1.09
-1.8%
First Trust Exchange-traded
$1.09
-1.8%
Trubridge Inc
$1.09
-1.8%
Stone Ridge 2049 Inflation-protected Longevity Income Etf
$1.09
-1.8%
Bbb Foods Inc.
$1.09
-1.8%
Spdr Ssga Us Eq Prem Inc Etf
$1.09
-1.8%
Embrace Change Acquisition Corp
$1.09
-1.8%
Powershares Kbw Bank Etf
$1.09
-1.8%